about
Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.New perspective for an old antidiabetic drug: metformin as anticancer agent.Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood.Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agentsCisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG)Up-regulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-Cl-cAMPVorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake
P50
Q33962243-41D08930-14B8-4074-A3B3-AB597A61D31CQ34363544-39F7305D-EE0C-49F3-8EFC-A79A5008B94EQ34376878-65B27AB6-27D0-406D-BE05-A5D22CAAA065Q34898391-932F04E4-E82A-4B2D-81C2-7A9A75FEA0E7Q35917810-C154505F-3A3A-4B9D-AFB0-AD06855C736FQ36109012-3CEAACB8-F87D-4FF7-B492-E41889E4EF13Q36946596-525EB196-8365-4EC7-8B53-7ACB22689EDDQ37066999-6C0A61C6-9414-451B-8CB1-722403A25360Q37190106-5A320713-4D64-4828-9CE2-6F59D29B1137Q37577433-A2D7199D-8A70-44EC-8435-C9A6347C949DQ38149290-E1533F94-47BB-4BD5-94A7-68159ED0F311Q39042562-AA655FEF-D72C-4641-A5B3-3F6665A9135CQ39527047-72F17448-6789-419C-9E52-3BF40655B139Q40505626-A0A6230B-D2F3-4487-85DD-D54BD991C645Q40608911-E3292E67-AF05-4AA0-84F3-A9E56E1AD2F8Q46629247-F780CD64-5C3A-48BA-8F4E-0B76F5D84259Q46663571-8F2AE29B-F40C-4E6E-BFA6-36E84F3830DEQ57588995-3BC9674C-C3EF-4CA8-BB45-F630F3869805Q74044400-78C899F6-D12C-49B3-BD6B-DD7B2E472FC9Q77360912-76359049-EADC-42F8-8D46-0DD1D51B2F44Q92689135-A7DC6529-CAEA-4CA6-A2B1-173F2E1D8B70
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elena Di Gennaro
@ast
Elena Di Gennaro
@en
Elena Di Gennaro
@es
Elena Di Gennaro
@nl
type
label
Elena Di Gennaro
@ast
Elena Di Gennaro
@en
Elena Di Gennaro
@es
Elena Di Gennaro
@nl
prefLabel
Elena Di Gennaro
@ast
Elena Di Gennaro
@en
Elena Di Gennaro
@es
Elena Di Gennaro
@nl
P106
P1153
6603409435
P21
P31
P496
0000-0001-6223-7845